Fabio Taborre suspended for adverse analytical finding of EPO-stimulating drug
Androni Giocattoli-Sidermec faces suspension for second failed test in 2015
Don't miss a moment from Paris-Roubaix and Unbound Gravel, to the Giro d’Italia, Tour de France, Vuelta a España, and everything in between when you join Outside+.
The UCI has notified Fabio Taborre (Androni Giocattoli-Sidermec) of an adverse analytical finding of FG-4592, a prohibited substance that stimulates the endogenous production of EPO, in a sample collected during an out-of-competition test on June 16, 2015.
Taborre has the right to request and attend the analysis of the B sample, but has been provisionally suspended until the adjudication of the matter.
Taborre’s failed test constitutes the second adverse analytical finding for an Androni Giocattoli-Sidermec rider since the beginning of 2015—Davide Appollonio was suspended for EPO in June. In accordance with new UCI rules, the team therefore faces a suspension of between 15 and 45 days. The UCI will refer the matter to its Disciplinary Commission, which will render a decision in the upcoming days.